Given that PAR-2 activation is known to engage downstream MAPK cascades that drive proliferative and inflammatory responses in colorectal cancer, we next investigated whether atorvastatin and rosuvastatin could attenuate ERK1/2 signalling, a principal effector arm of the PAR-2/MAPK axis. The gene discussed is F2RL1; the disease is colorectal cancer.